Cargando…
The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study
BACKGROUND: Anti-angiogenesis therapy has been a vital treatment option in a variety of cancers. Assessing the efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer is essential. METHODS: Thirty patients with end-stage cancer who were heavily pretreated were enrolled i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174995/ https://www.ncbi.nlm.nih.gov/pubmed/37180651 http://dx.doi.org/10.21037/tcr-22-2080 |
_version_ | 1785040153303056384 |
---|---|
author | Li, Zhenyu Zhou, Xiaoshu Wang, Shuai Shi, Liangliang Meng, Rui Dai, Xiaofang Liu, Yi Lin, Xueke Xiao, Yong Peng, Gang |
author_facet | Li, Zhenyu Zhou, Xiaoshu Wang, Shuai Shi, Liangliang Meng, Rui Dai, Xiaofang Liu, Yi Lin, Xueke Xiao, Yong Peng, Gang |
author_sort | Li, Zhenyu |
collection | PubMed |
description | BACKGROUND: Anti-angiogenesis therapy has been a vital treatment option in a variety of cancers. Assessing the efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer is essential. METHODS: Thirty patients with end-stage cancer who were heavily pretreated were enrolled in this study. All patients received oral administration of apatinib (125–500 mg/d) between May 2015 and November 2016. Dose reduction or elevation was conducted based on adverse events and doctors’ judgments. RESULTS: Prior to the apatinib treatment, the enrolled patients received a median of 1.2 surgeries (range, 0–7), 1.6 sessions of radiotherapies (range, 0–6), and 10.2 cycles of chemotherapy (range, 0–60); 43.3% of patients had uncontrolled local lesions, 83.3% of patients had uncontrolled multiple metastases, and 30.0% of patients had both. After the treatment, 25 patients had valuable data, 6 (24.0%) patients achieved partial response (PR), and 12 (48.0%) patients had stable disease (SD). The disease control rate (DCR) was 72.0%. The PR and SD rates were 20.0% and 40.0%, respectively, and the DCR was 60.0% in the intent-to-treat (ITT) analysis. Meanwhile, the median progression-free survival (PFS) was 2.6 (range, 0.7–5.4) months, and the median overall survival (OS) was 3.8 (range, 1.0–12.0) months. Furthermore, the PR rate and DCR in patients with squamous cell cancer (SCC) were 45.5% and 81.8%, respectively; those in patients with adenocarcinoma (ADC) were 8.3% and 58.3%, respectively. The adverse events were generally mild. The most common adverse events were hyperbilirubinemia (53.3%), elevated transaminase (36.7%), anemia (30.0%), thrombocytopenia (30.0%), hematuria (30.0%), fatigue (26.7%), and leukopenia (20.0%). CONCLUSIONS: The results of this study demonstrate the efficacy and safety of apatinib and support the further development of apatinib as a potential treatment option for patients with heavily pretreated end-stage cancer. |
format | Online Article Text |
id | pubmed-10174995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-101749952023-05-12 The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study Li, Zhenyu Zhou, Xiaoshu Wang, Shuai Shi, Liangliang Meng, Rui Dai, Xiaofang Liu, Yi Lin, Xueke Xiao, Yong Peng, Gang Transl Cancer Res Original Article BACKGROUND: Anti-angiogenesis therapy has been a vital treatment option in a variety of cancers. Assessing the efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer is essential. METHODS: Thirty patients with end-stage cancer who were heavily pretreated were enrolled in this study. All patients received oral administration of apatinib (125–500 mg/d) between May 2015 and November 2016. Dose reduction or elevation was conducted based on adverse events and doctors’ judgments. RESULTS: Prior to the apatinib treatment, the enrolled patients received a median of 1.2 surgeries (range, 0–7), 1.6 sessions of radiotherapies (range, 0–6), and 10.2 cycles of chemotherapy (range, 0–60); 43.3% of patients had uncontrolled local lesions, 83.3% of patients had uncontrolled multiple metastases, and 30.0% of patients had both. After the treatment, 25 patients had valuable data, 6 (24.0%) patients achieved partial response (PR), and 12 (48.0%) patients had stable disease (SD). The disease control rate (DCR) was 72.0%. The PR and SD rates were 20.0% and 40.0%, respectively, and the DCR was 60.0% in the intent-to-treat (ITT) analysis. Meanwhile, the median progression-free survival (PFS) was 2.6 (range, 0.7–5.4) months, and the median overall survival (OS) was 3.8 (range, 1.0–12.0) months. Furthermore, the PR rate and DCR in patients with squamous cell cancer (SCC) were 45.5% and 81.8%, respectively; those in patients with adenocarcinoma (ADC) were 8.3% and 58.3%, respectively. The adverse events were generally mild. The most common adverse events were hyperbilirubinemia (53.3%), elevated transaminase (36.7%), anemia (30.0%), thrombocytopenia (30.0%), hematuria (30.0%), fatigue (26.7%), and leukopenia (20.0%). CONCLUSIONS: The results of this study demonstrate the efficacy and safety of apatinib and support the further development of apatinib as a potential treatment option for patients with heavily pretreated end-stage cancer. AME Publishing Company 2023-03-27 2023-04-28 /pmc/articles/PMC10174995/ /pubmed/37180651 http://dx.doi.org/10.21037/tcr-22-2080 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Li, Zhenyu Zhou, Xiaoshu Wang, Shuai Shi, Liangliang Meng, Rui Dai, Xiaofang Liu, Yi Lin, Xueke Xiao, Yong Peng, Gang The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
title | The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
title_full | The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
title_fullStr | The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
title_full_unstemmed | The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
title_short | The efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
title_sort | efficacy and safety of apatinib in patients with heavily pretreated end-stage cancer: a retrospective study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174995/ https://www.ncbi.nlm.nih.gov/pubmed/37180651 http://dx.doi.org/10.21037/tcr-22-2080 |
work_keys_str_mv | AT lizhenyu theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT zhouxiaoshu theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT wangshuai theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT shiliangliang theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT mengrui theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT daixiaofang theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT liuyi theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT linxueke theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT xiaoyong theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT penggang theefficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT lizhenyu efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT zhouxiaoshu efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT wangshuai efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT shiliangliang efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT mengrui efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT daixiaofang efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT liuyi efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT linxueke efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT xiaoyong efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy AT penggang efficacyandsafetyofapatinibinpatientswithheavilypretreatedendstagecanceraretrospectivestudy |